Prev Close | 23.45 |
Day Low/High | 22.85 / 23.57 |
52 Wk Low/High | 18.76 / 25.10 |
Prev Close | 23.45 |
Day Low/High | 22.85 / 23.57 |
52 Wk Low/High | 18.76 / 25.10 |
Exchange | |
Shares Outstanding | 162.84B |
Market Cap | 3.82B |
Div & Yield | N.A. (N.A) |
Billionaire Bill Ackman's recent appointment to the troubled drugmaker's board could signal a meanful change of direction.
Jim Cramer says the antitrust environment out there will make it difficult for any railroad mergers to be approved by regulators.
Investors are gearing up for another assessment of the global economy, as the Fed Prepares to release the minutes of its March meeting.
Jim Cramer says the merger between Pfizer and Allergan isn't going anywhere, as lawmakers try to limit corporate inversions.
TheStreet's Jim Cramer said Valeant Pharmaceuticals' (VRX) move to appoint billionaire investor Bill Ackman to the board of directors isn't enough and a government monitor is needed.
Amazon is among the indicators.
And four other things you need to know now.
But investors are likely to be wary ahead of the Fed meeting.
TheStreet’s Jim Cramer answers your Twitter questions from the floor of the New York Stock Exchange.
Deals coming fast and furious in the best group in town.
Acquisitions cut into overabundance of companies.
Don't get me started ... wait, DO get me started.
Stocks hovered around the flat line in midday trading Monday with the Dow and the S&P 500 slightly down and the Nasdaq inching slightly higher.
China cut rates again but all eyes are now on Greece.
Cramer says it can't stay 'moribund that much longer.'
For the week of May 11 we await results from Actavis (ACT), Sotheby's (BID), GoDaddy (GDDY), Cisco Systems (CSCO), Macy's (M), Shake Shack (SHAK), Applied Materials (AMAT), and Petrobras (PBR).
Days like this can be very dispiriting.
Here's what stocks would do well with a strong dollar.
How do people get back into domestic stocks if there's no hook?
Rotation is just starting and can't be turned quickly.
Biotech companies are saying, "I do."
Teva bid highlights M&A action in health care sector.
Teva bid highlights M&A action in health care sector.
These companies are the hottest thing going.
The ecstasy and the agony of M&A all in one day.
There are much more important things going on.
There are dozens of juicy opportunities in this market.